Clovis Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Clovis Oncology generated cash of -$196,057,000, which is more than the previous year. Cash used in financing activities reached the amount of $100,157,000 last year. Net change in cash is therefore -$96,801,000.
Cash Flow
| 2012 | -65.38M | 942K | 70.29M |
|---|---|---|---|
| 2013 | -71.71M | -10.03M | 260.84M |
| 2014 | -117.05M | -2.28M | 279.47M |
| 2015 | -253.06M | -254.57M | 304.48M |
| 2016 | -266.68M | 199.29M | 5.17M |
| 2017 | -260.90M | -54.10M | 562.07M |
| 2018 | -365.99M | -264.24M | 388.46M |
| 2019 | -323.61M | 143.39M | 119.88M |
| 2020 | -252.72M | 126.32M | 203.64M |
| 2021 | -196.05M | -312K | 100.15M |
CLVS Cash Flow Statement (2012 â 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 240.22M | 161.83M | 221.87M | 464.19M | 216.18M | 278.75M | 482.67M | 323.22M | 144.09M | 138.23M |
Operating activities | ||||||||||
Net income | -264.52M | -369.21M | -400.42M | -368.00M | -346.39M | -349.13M | -352.86M | -160.03M | -84.53M | -73.98M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 8.49M | 8.19M | 7.76M | 4.60M | 2.50M | 1.14M | 761K | 4.22M | 250K | 353K |
Stock-based compensation expense | 25.45M | 50.79M | 54.30M | 49.09M | 44.70M | 39.79M | 40.35M | 21.51M | 9.50M | 4.94M |
| Deferred income tax benefit | 25.45M | 50.79M | 54.30M | 49.09M | 44.70M | 39.79M | 40.35M | 21.51M | 9.50M | 4.94M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -746K | -5.40M | -7.51M | -3.37M | -6.06M | -121K | 0 | 0 | 0 | 0 |
Inventories | 12.57M | 5.32M | -26.16M | -49.93M | -27.50M | -7.49M | 0 | 0 | 0 | 0 |
Accounts payable | 736K | -5.85M | 12.28M | 5.77M | 5.63M | -1.54M | 8.10M | -1.36M | 958K | -758K |
Cash generated by operating activities | -196.05M | -252.72M | -323.61M | -365.99M | -260.90M | -266.68M | -253.06M | -117.05M | -71.71M | -65.38M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -9.96M | -459.83M | -500M | -263.5M | 0 | -392.54M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -312K | -8.35M | -19.04M | -64.24M | -4.10M | -766K | -3.03M | -2.28M | -121K | -1.05M |
Acquisitions Net | 0 | 8M | 15.75M | 55M | 1.1M | 0 | -140.99M | 0 | -9.91M | 0 |
Cash generated by investing activities | -312K | 126.32M | 143.39M | -264.24M | -54.10M | 199.29M | -254.57M | -2.28M | -10.03M | 942K |
Financing activities | ||||||||||
Common Stock Issued | 116.92M | 246.66M | 0 | 93.89M | 545.83M | 0 | 298.50M | 0 | 259.07M | 69.97M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -65.41M | -166.12M | 0 | -280K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 100.15M | 203.64M | 119.88M | 388.46M | 562.07M | 5.17M | 304.48M | 279.47M | 260.84M | 70.29M |
Net Change In Cash | -96.80M | 78.39M | -60.04M | -242.32M | 248.01M | -62.57M | -203.92M | 159.44M | 179.13M | 5.86M |
Cash at end of period | 143.42M | 240.22M | 161.83M | 221.87M | 464.19M | 216.18M | 278.75M | 482.67M | 323.22M | 144.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |